Activating alleles of JAK3 in acute megakaryoblastic leukemia

Cancer Cell

Volumn 10, Issue 1, 2006, Pages 65-75

  Walters, Denise K ^a,b   Mercher, Thomas ^c   Gu, Ting Lei ^d   O'Hare, Thomas ^a,b   Tyner, Jeffrey W ^b   Loriaux, Marc ^e   Goss, Valerie L ^d   Lee, Kimberly A ^d   Eide, Christopher A ^b   Wong, Matthew J ^b   Stoffregen, Eric P ^b   McGreevey, Laura ^f   Nardone, Julie ^d   Moore, Sandra A ^c   Crispino, John ^g   Boggon, Titus J ^h   Heinrich, Michael C ^b,f   Deininger, Michael W ^b   Polakiewicz, Roberto D ^d   Gilliland, D Gary ^c   Druker, Brian J ^a,b   more..

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d CELL SIGNALING TECHNOLOGY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f PORTLAND VA MEDICAL CENTER   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CELLCYCLE

Indexed keywords

JANUS KINASE 3; TYROSINE;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CANCER SCREENING; CELL IMMORTALIZATION; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE ACTIVATION; GENE MUTATION; LEUKEMOGENESIS; MASS SPECTROMETRY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEOMICS;

MURINAE;

EID: 33745713168     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.06.002     Document Type: Article

References (66)

1. Atwell S., Adams J.M., Badger J., Buchanan M.D., Feil I.K., Froning K.J., Gao X., Hendle J., Keegan K., Leon B.C., et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J. Biol. Chem. 279 (2004) 55827-55832
2. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
3. Birkenkamp K.U., Geugien M., Lemmink H.H., Kruijer W., and Vellenga E. Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia 15 (2001) 1923-1931
4. Boggon T.J., Li Y., Manley P.W., and Eck M.J. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106 (2005) 996-1002
5. Borie D.C., O'Shea J.J., and Changelian P.S. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol. Med. 10 (2004) 532-541
6. Brown M.P., Nosaka T., Tripp R.A., Brooks J., van Deursen J.M., Brenner M.K., Doherty P.C., and Ihle J.N. Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3. Blood 94 (1999) 1906-1914
7. Cetkovic-Cvrlje M., and Tibbles H.E. Therapeutic potential of Janus kinase 3 (JAK3) inhibitors. Curr. Pharm. Des. 10 (2004) 1767-1784
8. Cetkovic-Cvrlje M., Dragt A.L., Vassilev A., Liu X.P., and Uckun F.M. Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. Clin. Immunol. 106 (2003) 213-225
9. Changelian P.S., Flanagan M.E., Ball D.J., Kent C.R., Magnuson K.S., Martin W.H., Rizzuti B.J., Sawyer P.S., Perry B.D., Brissette W.H., et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302 (2003) 875-878
10. Chen M., Cheng A., Candotti F., Zhou Y.J., Hymel A., Fasth A., Notarangelo L.D., and O'Shea J.J. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol. Cell. Biol. 20 (2000) 947-956
11. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., Teague J., Butler A., Edkins S., Stevens C., et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 65 (2005) 7591-7595
12. Flores-Morales A., Pircher T.J., Silvennoinen O., Gustafsson J.A., Sanchez-Gomez M., Norstedt G., Haldosen L.A., and Wood T.J. In vitro interaction between STAT 5 and JAK 2; dependence upon phosphorylation status of STAT 5 and JAK 2. Mol. Cell. Endocrinol. 138 (1998) 1-10
13. Fujitani Y., Hibi M., Fukada T., Takahashi-Tezuka M., Yoshida H., Yamaguchi T., Sugiyama K., Yamanaka Y., Nakajima K., and Hirano T. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT. Oncogene 14 (1997) 751-761
14. Goemans B.F., Zwaan C.M., Miller M., Zimmermann M., Harlow A., Meshinchi S., Loonen A.H., Hahlen K., Reinhardt D., Creutzig U., et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19 (2005) 1536-1542
15. Hall B.M. Cells mediating allograft rejection. Transplantation 51 (1991) 1141-1151
16. Hayakawa F., Towatari M., Iida H., Wakao H., Kiyoi H., Naoe T., and Saito H. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. Br. J. Haematol. 101 (1998) 521-528
17. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
18. Jin L., Pluskey S., Petrella E.C., Cantin S.M., Gorga J.C., Rynkiewicz M.J., Pandey P., Strickler J.E., Babine R.E., Weaver D.T., and Seidl K.J. The three-dimensional structure of the ZAP-70 kinase domain in complex with staurosporine: implications for the design of selective inhibitors. J. Biol. Chem. 279 (2004) 42818-42825
19. Johnston J.A., Kawamura M., Kirken R.A., Chen Y.Q., Blake T.B., Shibuya K., Ortaldo J.R., McVicar D.W., and O'Shea J.J. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 370 (1994) 151-153
20. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., Score J., Seear R., Chase A.J., Grand F.H., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
21. Kawahara A., Minami Y., Miyazaki T., Ihle J.N., and Taniguchi T. Critical role of the interleukin 2 (IL-2) receptor gamma-chain-associated Jak3 in the IL-2-induced c-fos and c-myc, but not bcl-2, gene induction. Proc. Natl. Acad. Sci. USA 92 (1995) 8724-8728
22. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352 (2005) 1779-1790
23. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353 (2005) 172-187
24. Lacronique V., Boureux A., Monni R., Dumon S., Mauchauffe M., Mayeux P., Gouilleux F., Berger R., Gisselbrecht S., Ghysdael J., and Bernard O.A. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 95 (2000) 2076-2083
25. Lai K.S., Jin Y., Graham D.K., Witthuhn B.A., Ihle J.N., and Liu E.T. A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells. J. Biol. Chem. 270 (1995) 25028-25036
26. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
27. Li Z., Godinho F.J., Klusmann J.H., Garriga-Canut M., Yu C., and Orkin S.H. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat. Genet. 37 (2005) 613-619
28. Lindauer K., Loerting T., Liedl K.R., and Kroemer R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 14 (2001) 27-37
29. Malaviya R., Zhu D., Dibirdik I., and Uckun F.M. Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. J. Biol. Chem. 274 (1999) 27028-27038
30. Migone T.S., Lin J.X., Cereseto A., Mulloy J.C., O'Shea J.J., Franchini G., and Leonard W.J. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269 (1995) 79-81
31. Miyazaki T., Kawahara A., Fujii H., Nakagawa Y., Minami Y., Liu Z.J., Oishi I., Silvennoinen O., Witthuhn B.A., Ihle J.N., et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 266 (1994) 1045-1047
32. Na Nakorn T., Traver D., Weissman I.L., and Akashi K. Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J. Clin. Invest. 109 (2002) 1579-1585
33. Noguchi M., Nakamura Y., Russell S.M., Ziegler S.F., Tsang M., Cao X., and Leonard W.J. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science 262 (1993) 1877-1880
34. Nosaka T., van Deursen J.M., Tripp R.A., Thierfelder W.E., Witthuhn B.A., McMickle A.P., Doherty P.C., Grosveld G.C., and Ihle J.N. Defective lymphoid development in mice lacking Jak3. Science 270 (1995) 800-802
35. Notarangelo L.D., Mella P., Jones A., de Saint Basile G., Savoldi G., Cranston T., Vihinen M., and Schumacher R.F. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum. Mutat. 18 (2001) 255-263
36. O'Farrell A.M., Foran J.M., Fiedler W., Serve H., Paquette R.L., Cooper M.A., Yuen H.A., Louie S.G., Kim H., Nicholas S., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin. Cancer Res. 9 (2003) 5465-5476
37. O'Shea J.J., Pesu M., Borie D.C., and Changelian P.S. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat. Rev. Drug Discov. 3 (2004) 555-564
38. Parang K., Till J.H., Ablooglu A.J., Kohanski R.A., Hubbard S.R., and Cole P.A. Mechanism-based design of a protein kinase inhibitor. Nat. Struct. Biol. 8 (2001) 37-41
39. Paul M.K., and Mukhopadhyay A.K. Tyrosine kinase-Role and significance in Cancer. Int. J. Med. Sci. 1 (2004) 101-115
40. Peng J., Elias J.E., Thoreen C.C., Licklider L.J., and Gygi S.P. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J. Proteome Res. 2 (2003) 43-50
41. Pesu M., Candotti F., Husa M., Hofmann S.R., Notarangelo L.D., and O'Shea J.J. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol. Rev. 203 (2005) 127-142
42. Rappsilber J., Ishihama Y., and Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal. Chem. 75 (2003) 663-670
43. Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., Zha X.M., Polakiewicz R.D., and Comb M.J. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat. Biotechnol. 23 (2005) 94-101
44. Russell S.M., Johnston J.A., Noguchi M., Kawamura M., Bacon C.M., Friedmann M., Berg M., McVicar D.W., Witthuhn B.A., Silvennoinen O., et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 266 (1994) 1042-1045
45. Saharinen P., and Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277 (2002) 47954-47963
46. Sato T., Fuse A., Eguchi M., Hayashi Y., Ryo R., Adachi M., Kishimoto Y., Teramura M., Mizoguchi H., Shima Y., et al. Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryoblastic leukaemia. Br. J. Haematol. 72 (1989) 184-190
47. Schwaller J., Frantsve J., Aster J., Williams I.R., Tomasson M.H., Ross T.S., Peeters P., Van Rompaey L., Van Etten R.A., Ilaria Jr. R., et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17 (1998) 5321-5333
48. Schwede T., Kopp J., Guex N., and Peitsch M.C. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 31 (2003) 3381-3385
49. Sohn S.J., Forbush K.A., Nguyen N., Witthuhn B., Nosaka T., Ihle J.N., and Perlmutter R.M. Requirement for Jak3 in mature T cells: its role in regulation of T cell homeostasis. J. Immunol. 160 (1998) 2130-2138
50. Staerk J., Kallin A., Demoulin J.B., Vainchenker W., and Constantinescu S.N. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J. Biol. Chem. 280 (2005) 41893-41899
51. Stamos J., Sliwkowski M.X., and Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277 (2002) 46265-46272
52. Stepkowski S.M., Erwin-Cohen R.A., Behbod F., Wang M.E., Qu X., Tejpal N., Nagy Z.S., Kahan B.D., and Kirken R.A. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 99 (2002) 680-689
53. Stirewalt D.L., and Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 3 (2003) 650-665
54. Thomis D.C., Gurniak C.B., Tivol E., Sharpe A.H., and Berg L.J. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270 (1995) 794-797
55. Tian J., Olcott A.P., Hanssen L.R., Zekzer D., Middleton B., and Kaufman D.L. Infectious Th1 and Th2 autoimmunity in diabetes-prone mice. Immunol. Rev. 164 (1998) 119-127
56. Tortolani P.J., Lal B.K., Riva A., Johnston J.A., Chen Y.Q., Reaman G.H., Beckwith M., Longo D., Ortaldo J.R., Bhatia K., et al. Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J. Immunol. 155 (1995) 5220-5226
57. Tse K.F., Mukherjee G., and Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 14 (2000) 1766-1776
58. Walters D.K., Stoffregen E.P., Heinrich M.C., Deininger M.W., and Druker B.J. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood 105 (2005) 2952-2954
59. Walters D.K., Goss V.L., Stoffregen E.P., Gu T.L., Lee K., Nardone J., McGreevey L., Heinrich M.C., Deininger M.W., Polakiewicz R., and Druker B.J. Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk Res. (2006) 10.1016/j.leukres.2006.01.001 Published online February 4, 2006
60. Wechsler J., Greene M., McDevitt M.A., Anastasi J., Karp J.E., Le Beau M.M., and Crispino J.D. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat. Genet. 32 (2002) 148-152
61. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., and Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 (2006) 4274-4281
62. Witthuhn B.A., Silvennoinen O., Miura O., Lai K.S., Cwik C., Liu E.T., and Ihle J.N. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 370 (1994) 153-157
63. Xu X., Kang S.H., Heidenreich O., Okerholm M., O'Shea J.J., and Nerenberg M.I. Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells. J. Clin. Invest. 96 (1995) 1548-1555
64. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., Asou N., Kuriyama K., Yagasaki F., Shimazaki C., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97 (2001) 2434-2439
65. Yokota S., Kiyoi H., Nakao M., Iwai T., Misawa S., Okuda T., Sonoda Y., Abe T., Kahsima K., Matsuo Y., and Naoe T. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11 (1997) 1605-1609
66. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., and Zhao Z.J. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280 (2005) 22788-22792